Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas.

PubWeight™: 1.06‹?› | Rank: Top 15%

🔗 View Article (PMID 9120716)

Published in J Pathol on February 01, 1997

Authors

I K Bukholm1, J M Nesland, R Kåresen, U Jacobsen, A L Børresen

Author Affiliations

1: Genetic Department Norwegian Radium Hospital, University of Oslo, Norway.

Articles by these authors

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med (1996) 7.32

5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer (1997) 2.64

Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med (1992) 2.64

Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [seecomments]. J Pathol (2000) 2.61

Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol (2008) 2.37

Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol (2003) 2.13

Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy (1999) 1.83

Metaplastic breast carcinomas are basal-like tumours. Histopathology (2006) 1.80

Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A (2001) 1.80

5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol (1997) 1.79

Familial testicular cancer in Norway and southern Sweden. Br J Cancer (1996) 1.76

Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res (2001) 1.75

Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A (1991) 1.65

Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III). Breast Cancer Res Treat (1999) 1.63

Molecular heterogeneity in the mild autosomal dominant forms of osteogenesis imperfecta. Am J Hum Genet (1984) 1.62

E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol (1998) 1.61

Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol (2001) 1.54

Nude rat model for studying metastasis of human tumor cells to bone and bone marrow. J Natl Cancer Inst (1990) 1.53

Molecular genetic changes in human male germ cell tumors. Lab Invest (1995) 1.53

Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J Clin Oncol (2000) 1.51

Small cell carcinoma of the ovary. A report of six cases. Int J Gynecol Pathol (1988) 1.51

TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus. J Pathol (1999) 1.44

Consequences of routine peroperative cholangiography during cholecystectomy for gallstone disease: a prospective, randomized study. World J Surg (1986) 1.44

Deletion of 1p loci and microsatellite instability in colorectal polyps. Genes Chromosomes Cancer (1995) 1.43

Predictive ability of choledocholithiasis indicators. A prospective evaluation. Ann Surg (1985) 1.42

High-density lipoprotein as carrier for amyloid-related protein SAA in rabbit serum. Scand J Immunol (1979) 1.41

High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis (1999) 1.40

DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene (2007) 1.40

Marfan syndrome: exclusion of genetic linkage to the COL1A2 gene. Clin Genet (1986) 1.40

Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics (1995) 1.39

[Telepathology at the Norwegian Radium Hospital]. Tidsskr Nor Laegeforen (2000) 1.39

Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene (2000) 1.38

Expression of laminin, collagen IV, fibronectin, and type IV collagenase in gastric carcinoma. An immunohistochemical study of 87 patients. Cancer (1994) 1.31

A segregation analysis of testicular cancer based on Norwegian and Swedish families. Br J Cancer (1997) 1.31

High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res (1997) 1.30

Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer (1993) 1.30

Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res (1988) 1.29

Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct Pathol (1996) 1.29

Distribution and photosensitizing efficiency of porphyrins induced by application of exogenous 5-aminolevulinic acid in mice bearing mammary carcinoma. Int J Cancer (1992) 1.26

Mammography screening in Norway: results from the first screening round in four counties and cost-effectiveness of a modeled nationwide screening. Cancer Causes Control (2001) 1.26

Pessimism as a predictor of emotional morbidity one year following breast cancer surgery. Psychooncology (2004) 1.25

Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol (1998) 1.23

Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas. Genes Chromosomes Cancer (1992) 1.22

A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX. Int J Cancer (1988) 1.21

Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer (2001) 1.21

Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res (1994) 1.21

Build-up of esterified aminolevulinic-acid-derivative-induced porphyrin fluorescence in normal mouse skin. J Photochem Photobiol B (1996) 1.19

Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res (2000) 1.19

Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet (1994) 1.18

Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol (1998) 1.17

Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J Pathol (1993) 1.16

Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch (2000) 1.16

Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proc Natl Acad Sci U S A (1992) 1.15

p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res (1994) 1.15

CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. Cancer Res (1999) 1.14

A common BRCA1 mutation in Norwegian breast and ovarian cancer families? Am J Hum Genet (1996) 1.12

SYBR green I DNA staining increases the detection sensitivity of viruses by polymerase chain reaction. J Virol Methods (1995) 1.12

Genetic alterations within the retinoblastoma locus in colorectal carcinomas. Relation to DNA ploidy pattern studied by flow cytometric analysis. Br J Cancer (1991) 1.12

Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection. Mutat Res (1991) 1.12

Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncol (1995) 1.11

Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity. Oncogene (2001) 1.09

Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma. Int J Cancer (1986) 1.09

Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer (2004) 1.08

Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol (1993) 1.08

p53 abnormalities in different subtypes of human sarcomas. Cancer Res (1993) 1.07

The gene for apolipoprotein C-II is closely linked to the gene for apolipo-protein E on chromosome 19. Clin Genet (1984) 1.07

Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies. Br J Cancer (2002) 1.07

Simple mucin-type carbohydrate antigens (Tn, sialosyl-Tn and T) in gastric mucosa, carcinomas and metastases. APMIS Suppl (1992) 1.07

Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol (1999) 1.07

Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics. Clin Cancer Res (2001) 1.06

[Late diagnosis of advanced breast cancer--a challenge for health services]. Tidsskr Nor Laegeforen (1992) 1.06

Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM. Genes Chromosomes Cancer (1997) 1.05

Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics (1991) 1.05

Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. Br J Cancer (1990) 1.04

Disseminated tumour cells as a prognostic biomarker in colorectal cancer. Br J Cancer (2011) 1.04

Small cell carcinoma of the cervix. A clinicopathologic study of 26 patients. Cancer (1994) 1.02

Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer (1996) 1.02

Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome. J Clin Pathol (2005) 1.02

Loss of 3p or 11p alleles is associated with testicular cancer tumors. Genomics (1989) 1.01

Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Int J Cancer (1998) 1.01

P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res (2000) 1.01

Different apoptotic pathways are induced from various intracellular sites by tetraphenylporphyrins and light. Br J Cancer (1999) 1.01

Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas. J Clin Pathol (2003) 1.01

Uptake, localization, and photodynamic effect of meso-tetra(hydroxyphenyl)porphine and its corresponding chlorin in normal and tumor tissues of mice bearing mammary carcinoma. Cancer Res (1995) 1.00

Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection. Diagn Mol Pathol (1995) 1.00

E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol (2000) 1.00

Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B (2001) 0.99